Ngā hua rapu - Rafael Rosell

Whakamahine hua
  1. 1
    Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC)

    Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC) mā Irene Moya‐Horno, Santiago Viteri, Niki Karachaliou, Rafael Rosell

    I whakaputaina 2018
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  2. 2
    Mechanisms of resistance to osimertinib

    Mechanisms of resistance to osimertinib mā Chiara Lazzari, Vanesa Gregorc, Niki Karachaliou, Rafael Rosell, Mariacarmela Santarpía

    I whakaputaina 2020
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  3. 3
    Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy

    Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy mā Enriqueta Felip, Cesare Gridelli, Paul Baas, Rafael Rosell, Rolf A. Stahel

    I whakaputaina 2011
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  4. 4
    EGFR first- and second-generation TKIs—there is still place for them in EGFR-mutant NSCLC patients

    EGFR first- and second-generation TKIs—there is still place for them in EGFR-mutant NSCLC patients mā Niki Karachaliou, Manuel Fernández-Bruno, Jillian Wilhelmina Paulina Bracht, Rafael Rosell

    I whakaputaina 2018
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  5. 5
    Nucleotide Excision Repair Pathways Involved in Cisplatin Resistance in Non-Small-Cell Lung Cancer

    Nucleotide Excision Repair Pathways Involved in Cisplatin Resistance in Non-Small-Cell Lung Cancer mā Rafael Rosell, Miquel Tarón, Agustí Barnadas, Giorgio V. Scagliotti, Carme Sarries, Bárbara Roig

    I whakaputaina 2003
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  6. 6
    Clinical assessment of immune-related adverse events

    Clinical assessment of immune-related adverse events mā Aaron E. Sosa, Esther Lopez Cadena, Cristina Simon Olivé, Niki Karachaliou, Rafael Rosell

    I whakaputaina 2018
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  7. 7
    A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations

    A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations mā Mariacarmela Santarpía, Marco Massafra, Vittorio Gebbia, A. d’Aquino, Claudia Garipoli, Giuseppe Altavilla, Rafael Rosell

    I whakaputaina 2021
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  8. 8
    Quality of Life During Chemotherapy in Non-Small Cell Lung Cancer Patients

    Quality of Life During Chemotherapy in Non-Small Cell Lung Cancer Patients mā C. Hernández Fernández, Rafael Rosell, A Abad-Esteve, P. Monras, I. Moreno, M. Serichol, M. Roviralta

    I whakaputaina 1989
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  9. 9
    Clinical outcomes in non‐small‐cell lung cancer patients with <i>EGFR</i> mutations: pooled analysis

    Clinical outcomes in non‐small‐cell lung cancer patients with <i>EGFR</i> mutations: pooled analysis mā Luis Paz‐Ares, Denis Soulières, I. Melezínek, Joachim Moecks, Lorenz Keil, Tony Mok, Rafael Rosell, Barbara Klughammer

    I whakaputaina 2010
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  10. 10
    Detection of chromosome 3p alterations in serum DNA of non-small-cell lung cancer patients

    Detection of chromosome 3p alterations in serum DNA of non-small-cell lung cancer patients mā Montse Sánchez‐Céspedes, Mariano Monzó, Rafael Rosell, Àlex Pifarré, Ran Calvo, M.P. López-Cabrerizo, I. Astudillo

    I whakaputaina 1998
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  11. 11
    The combination of checkpoint immunotherapy and targeted therapy in cancer

    The combination of checkpoint immunotherapy and targeted therapy in cancer mā Niki Karachaliou, Maria Gonzalez-Cao, Aaron E. Sosa, Jordi Berenguer, Jillian Wilhelmina Paulina Bracht, Masaoki Ito, Rafael Rosell

    I whakaputaina 2017
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  12. 12
    Coregulation of pathways in lung cancer patients with EGFR mutation: therapeutic opportunities

    Coregulation of pathways in lung cancer patients with EGFR mutation: therapeutic opportunities mā Rafael Rosell, Andrés F. Cardona, Óscar Arrieta, Andrés Aguilar, Masaoki Ito, Carlos Pedraz, Jordi Codony‐Servat, Mariacarmela Santarpía

    I whakaputaina 2021
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  13. 13
    Biological insights in non-small cell lung cancer

    Biological insights in non-small cell lung cancer mā Rafael Rosell, Anisha Jain, Jordi Codony‐Servat, Eloísa Jantus‐Lewintre, Blake Morrison, Jordi Barretina Ginesta, María González‐Cao

    I whakaputaina 2023
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  14. 14
    Allelic loss on chromosome 18q as a prognostic marker in stage II colorectal cancer

    Allelic loss on chromosome 18q as a prognostic marker in stage II colorectal cancer mā Eva Martínez-López, Albert Abad, Albert Font, Mariano Monzó, Isabel Ojanguren, Àlex Pifarré, José Javier Sánchez, Cristina Martîn, Rafael Rosell

    I whakaputaina 1998
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  15. 15
    Gene expression profiling reveals novel biomarkers in nonsmall cell lung cancer

    Gene expression profiling reveals novel biomarkers in nonsmall cell lung cancer mā Abel Sánchez‐Palencia, Mercedes Gómez‐Morales, José Antonio Gómez‐Capilla, V Pedraza, Laura Boyero, Rafael Rosell, Ma Esther Fárez‐Vidal

    I whakaputaina 2010
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  16. 16
    Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: is this the beginning of the end for cancer?

    Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: is this the beginning of the end for cancer? mā Chiara Lazzari, Niki Karachaliou, Alessandra Bulotta, Mariagrazia Viganò, Aurora Mirabile, Elena Brioschi, Mariacarmela Santarpía, Luca Gianni, Rafael Rosell, Vanesa Gregorc

    I whakaputaina 2018
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  17. 17
    Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy

    Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy mā Mariacarmela Santarpía, Alessia Liguori, Niki Karachaliou, María González‐Cao, Maria Grazia Daffinà, Alessandro D’Aveni, Grazia Marabello, Giuseppe Altavilla, Rafael Rosell

    I whakaputaina 2017
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  18. 18
    STAT3 as a potential immunotherapy biomarker in oncogene-addicted non-small cell lung cancer

    STAT3 as a potential immunotherapy biomarker in oncogene-addicted non-small cell lung cancer mā Ilaria Attili, Niki Karachaliou, Laura Bonanno, Jordi Berenguer, Jillian Wilhelmina Paulina Bracht, Jordi Codony‐Servat, Carles Codony, Masaoki Ito, Rafael Rosell

    I whakaputaina 2018
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Editorial
    Tiaki ki tētahi rārangi
    I tiakina i:
  19. 19
    Liquid biopsy for lung cancer early detection

    Liquid biopsy for lung cancer early detection mā Mariacarmela Santarpía, Alessia Liguori, Alessandro D’Aveni, Niki Karachaliou, María González‐Cao, Maria Grazia Daffinà, Chiara Lazzari, Giuseppe Altavilla, Rafael Rosell

    I whakaputaina 2018
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  20. 20
    Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine

    Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine mā John Souglakos, Ioannis Boukovinas, Miquel Tarón, Pedro Méndez, D. Mavroudis, M Tripaki, Dora Hatzidaki, Anastasios Koutsopoulos, Efstathios N. Stathopoulos, Vassilis Georgoulias, Rafael Rosell

    I whakaputaina 2008
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:

Ngā utauta rapu: